Erythrocyte Encapsulated Thiosulfate Sulfurtransferase

Way, James L.; Leung, P; Ray, Lee E.; Sander, Christian

doi:10.1159/000410230

Cited by 14 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Employing encapsulated enzymes as intravascular antidotes in antidotal therapy was first reported in the mid-1980s (Way et al 1985). Results with various encapsulated metabolizing enzymes (Way et al 1985(Way et al , 1991Petrikovics et al 1994Petrikovics et al , 1995Petrikovics et al , 2004 suggest that this approach can also serve as an effective tool in CN antidotal therapy.…”

Section: Discussionmentioning

confidence: 99%

Nano-intercalated rhodanese in cyanide antagonism

et al. 2010

View full text Add to dashboard Cite

Present studies have focused on nano-intercalated rhodanese in combination with sulfur donors to prevent cyanide lethality in a prophylactic mice model for future development of an effective cyanide antidotal system. Our approach is based on the idea of converting cyanide to the less toxic thiocyanate before it reaches the target organs by utilizing sulfurtransferases (e.g., rhodanese) and sulfur donors in a close proximity by injecting them directly into the blood stream. The inorganic thiosulfate (TS) and the garlic component diallydisulfide (DADS) were compared as sulfur donors with the nano-intercalated rhodanese in vitro and in vivo. The in vivo and in vitro experiments showed that DADS is not a more efficient sulfur donor than TS. However, the utilization of external rhodanese significantly enhanced the in vivo efficacy of both sulfur donor-nitrite combinations, indicating the potential usefulness of enzyme nano-delivery systems in developing antidotal therapeutic agents.

show abstract

Section: Discussionmentioning

confidence: 99%

Nano-intercalated rhodanese in cyanide antagonism

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Each data point is the average of triplicate assays; in all cases, the experimental error was less than 10% study demonstrates that the direct injection of appropriate amounts of enzyme can provide greater protection against the lethal effects of OP agents than the current treatment regimen of (2-PAM+atropine). The magnitude and duration of this protection are found to be greatly increased if enzymes are entrapped into drug delivery biocarriers such as sterically stabilized liposomes (16)(17)(18) or carrier red blood cells (6)(7)(8)(9)(10)(11). Employing tree-like (dendritic) polymer-based DP offers a number of advantages, including better water solubility, nontoxic nature, and most importantly, ease of encapsulation for delivery.…”

Section: Discussionmentioning

confidence: 99%

“…Subsequently, carrier red blood cells (CRBC) were evaluated as enzyme carriers, originally in cyanide antagonism (6)(7)(8)(9), and more recently in OP antagonism (10,11). In addition to the CRBC, these enzymes have been deployed with other enzyme delivery platforms, including sterically stabilized liposomes (SL) (12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Nano-Intercalated Organophosphorus-Hydrolyzing Enzymes in Organophosphorus Antagonism

et al. 2011

View full text Add to dashboard Cite

Abstract. A dendritic poly(2-alkyloxazoline)-based polymer was studied as a new carrier system for the organophosphorus-hydrolyzing recombinant enzymes, organophosphorus acid anhydrolase and organophosphorus hydrolase. Paraoxon (PO) and diisopropylfluorophosphate (DFP) were used as model organophosphorus compounds. Changes in plasma cholinesterase activity were monitored. The cholinesterase activity was proportional to the concentrations of DFP or PO. Plasma cholinesterase activity was higher in animals receiving enzyme and oxime before the organophosphates than in the oxime-only pretreated groups. These studies suggest that cholinesterase activity can serve as an indicator for the in vivo protection by the nano-intercalated organophosphorus acid anhydrolase or organophosphorus hydrolase against organophosphorus intoxications. These studies represent a practical application of polymeric nano-delivery systems as enzyme carriers in drug antidotal therapy.KEY WORDS: dendritic polymer; diisopropylfluorophosphate (DFP); organophosphorus acid anhydrolase (OPAA); paraoxon; 2-PAM.

show abstract

“…One of the antidotal mechanisms against CN involves employment of externally administered highly purified recombinant CN-metabolizing enzymes with high catalytic activity encapsulated within an appropriate enzyme carrier (Way et al, 1985). This antidotal approach is based on the idea of destroying the toxicant before it reaches the target organs.…”

Section: Introductionmentioning

confidence: 99%

“…glucocerebrosidase) replacement therapy for the congenital metabolic disorder termed Gaucher's disease (Beutler et al, 1977). RBCs encapsulating metabolizing enzymes were successfully employed in CN antagonism (Way et al, 1985;Leung et al, 1991; and in organophosphate (OP) antagonism . Although RBCs have an advantage of long circulation time (i.e.…”

Section: Introductionmentioning

confidence: 99%